New research into Alzheimer’s treatment and potential vaccine

new research into alzheimers treatment and potential vaccine

Sumary of New research into Alzheimer’s treatment and potential vaccine:

  • The research published in Molecular Psychiatry found that an antibody-based Alzheimer’s treatment and the protein-based vaccine developed by the team reduced Alzheimer’s symptoms in mouse models with the disease.
  • New Alzheimer’s treatment shown to reduce symptoms The amyloid beta protein in plaques in the brain is commonly associated with Alzheimer’s disease;
  • however, the antibody and vaccine both target a different soluble – a form of a protein that is thought to be highly toxic.
  • Amyloid beta protein exists as a highly flexible, string-like molecule in solution, which can join to form fibres and plaques.
  • Professor Thomas Bayer, from the University Medical Center Göttingen, said: “In clinical trials, none of the potential treatments which dissolve amyloid plaques in the brain have shown much success in terms of reducing Alzheimer’s symptoms.
  • We identified an antibody in mice that would neutralise the truncated forms of soluble amyloid beta but would not bind either to normal forms of the protein or to the plaques.
  • When the Leicester research group looked at how and where this ‘humanised’ antibody, called TAP01_04, was binding to the truncated form of amyloid beta, they found the amyloid beta protein was folded back on itself, in a hairpin-shaped structure.
  • Professor Mark Carr, from the Leicester Institute of Structural and Chemical Biology at the University of Leicester, explained: “This structure had never been seen before in amyloid beta.

Want to know more click here go to source.

From -


Site Language

By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.